Lilly Agrees to Buy US Biotech Morphic in $3.2 Billion Deal
(Bloomberg) -- Eli Lilly & Co. agreed to buy U.S. gut-drug maker Morphic Holding Inc. for about $3.2 billion, plowing some of the proceeds from obesity blockbuster Zepbound into its experimental pipeline.Most Read from BloombergLilly will pay $57 a share...

















